Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year
September 09, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
- 2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% year-over-year, respectively - NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent...
Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
September 05, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Amebocyte Lysate Market to Reach $1.9 Billion, Globally, by 2033 at 11.8% CAGR: Allied Market Research
September 04, 2024 04:54 ET
|
Allied Analytics LLP
Wilmington, Delaware, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Amebocyte Lysate Market by Type (Limulus Amebocyte Lysate and Tachypleus Amebocyte...
Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees
September 03, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant...
Drug Abuse Testing Market Report 2024: Emerging Trends, Regional Market Shares, Leading Companies, Strategic Opportunities, Industry Forecast to 2030
September 03, 2024 04:09 ET
|
Research and Markets
Dublin, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The "Drug Abuse Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Drug Abuse...
Intelligent Bio Solutions Inc. Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024
August 21, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leading innovator in non-invasive drug testing technology, today announced the...
Drug Abuse Testing Market Report By Drug Type, Product & Services, Sample Type, End Users Countries and Company Analysis - Global Forecast to 2032
August 13, 2024 11:19 ET
|
Research and Markets
Dublin, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The "Drug Abuse Testing Market Report By Drug Type, Product & Services, Sample Type, End Users Countries and Company Analysis 2024-2032" report has been...
Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries
August 13, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as...
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
August 01, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions Inc. (INBS) partners with CenExel to perform a method comparison clinical study as part of the Company’s FDA clinical study plan.
Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia
July 24, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...